The Magpie Trial: A randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years
Corfield N., Salter A., Thorn L., Altman D., Yu LM., Abalos E., Carroli B., Dellepiane L., Duarte M., Fernandez H., Giordano D., Clarke M., Gray A., Hey E., Neilson J., Simon J., Collins R., Karaoglou A., Lilford R., Moodley J., Robson S., Roberts I., Rubin P., Thornton J., Twaddle S., Villar J., Walker I., Watkins C., Doyle L., Bimbashi A., Demalia E., Gliozheni O., Shpata A., Karolinski A., Lamas M., Pesaresi M., Wainer V., Barbato W., Paciocco M., Bertin M., Boiza E., Castaldi J., Partida Y., Arias C., Farri M., Kerz G., Aguirre J., De Sagastizábal M., Falcone R., Morales E., Carroli G., Krupitzky S., López S., Palermo M., Montes Varela D., Delprato H., Camusso H., Curioni M., Ludmer E., Brandi R., Martin R., Mesas W., Taralli R., Lezaola M., Morosini M., Andina E., Bernal L., Estiú M., Ulens E., Ortiz De Speranza B., Peyrano A., Damiano M., Saumench C., Horn J., Pritchard M., Smith-Orr V., Wilson M., Lawrence A., Watson D., Crowther C., Paynter J., Ashrafunnessa None., Mannan M., Shahidullah M., Shamsuddin L., Barros Santos C., Freire S., Melo E., Cobo E., Jaramillo E., Cardozo C., Fandiño N.
Objective: The aim of this study was to assess long-term effects for women following the use of magnesium sulphate for pre-eclampsia. Design: Assessment at 2-3 years after delivery for women recruited to the Magpie Trial (recruitment in 1998-2001, ISRCTN 86938761), which compared magnesium sulphate with placebo for pre-eclampsia. Setting: Follow up after discharge from hospital at 125 centres in 19 countries across five continents. Population: A total of 7927 women were randomised at the follow-up centres. Of these women, 2544 were not included for logistic reasons and 601 excluded (109 at a centre where <20% of women were contacted, 466 discharged without a surviving child and 26 opted out). Therefore, 4782 women were selected for follow-up, of whom 3375 (71%) were traced. Methods: Questionnaire assessment was administered largely by post or in a dedicated clinic. Interview assessment of selected women was performed. Main outcome measures: Death or serious morbidity potentially related to pre-eclampsia at follow up, other morbidity and use of health service resources. Results: Median time from delivery to follow up was 26 months (interquartile range 19-36). Fifty-eight of 1650 (3.5%) women allocated magnesium sulphate died or had serious morbidity potentially related to pre-eclampsia compared with 72 of 1725 (4.2%) women allocated placebo (relative risk 0.84, 95% CI 0.60-1.18). Conclusions: The reduction in the risk of eclampsia following prophylaxis with magnesium sulphate was not associated with an excess of death or disability for the women after 2 years. © RCOG 2006 BJOG An International Journal of Obstetrics and Gynaecology.